BioMedNewsBreaks

ThursdayJun 17, 2021 1:28 pm

BioMedNewsBreaks – Galileo Life Sciences Inc. (MDRM) Issues Telehealth Progress Update

Galileo Life Sciences (OTC: MDRM), a company strategically focused on the telehealth and telemedicine industry, today provided an update on its progress in providing next-generation telehealth services. Innovations in telehealth have enabled health care providers with superior technology, allowing them to diagnose, treat and monitor the state of their patients with greater efficiency. However, video conferencing, the key tool in most telehealth technologies, limits the ability of physicians to check the patients' vitals. Galileo Life Sciences, through its partnerships with various technology organizations, has established a unique platform that is connected with medical devices, which enables physicians to check patients'…

Continue Reading

ThursdayJun 17, 2021 12:38 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set for Inclusion in Russell 2000 Index

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the company will be added to the Russell 2000(R) Index, effective June 25, 2021, after the close of the U.S. equity markets. CNSP will be added following the annual reconstitution of the Russell stock indexes. According to the announcement, the Russell 2000 Index, which is a subset of the Russell 3000(R) Index, measures the performance of the small-cap segment of the equity market in the United States and includes an estimated 2,000…

Continue Reading

ThursdayJun 17, 2021 10:53 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in Latest Episode of Bell2Bell Podcast

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, was featured in the Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. XPhyto Therapeutics’ CEO and Director Hugh Rogers joined the latest episode to offer an operational update and discuss the company’s achievements and future plans. XPhyto Therapeutics recently secured European approval and launched an effective 25-minute polymerase chain reaction (“PCR”) test for COVID-19 (“Covid-ID Lab”), with an initial focus on the German market and several other initiatives underway. “This is an exciting time for the company.…

Continue Reading

ThursdayJun 17, 2021 10:41 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Featured Guest in Latest Stock2Me Podcast

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced that chairman and CEO Greg McKee was interviewed on the most recent episode of the Stock2Me Podcast. The podcast features a fascinating array of companies and individuals that are actively revolutionizing business practices within their respective markets. In the interview, McKee talked about the objective of TRYP, which is fundamentally to help patients, as well as identifying and bringing new therapies to patients. McKee also discussed the need for innovation in the psychedelics space and Tryp’s upcoming human clinical…

Continue Reading

WednesdayJun 16, 2021 11:14 am

BioMedNewsBreaks — Brain Scientific Inc. (BRSF) Announces Acquisition Agreement

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has entered into a definitive merger agreement to acquire Piezo Motion Corp., a leading innovator of high-precision piezoelectric motion technology. According to the announcement, the merger is designed to expand the market reach of both companies along with their ability to deliver innovative technologies to high-growth markets. Both companies have built impressive teams of scientists, engineers and executives with invaluable expertise in developing and commercializing disruptive technologies, and the acquisition will result in a single company with vast machine learning background and astute ability to address demands in the market. Currently, BRSF’s…

Continue Reading

TuesdayJun 15, 2021 1:59 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Create Safer, More Effective Protocol in ‘Fast-Moving Arena of Psychedelic Therapies’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is collaborating with psychedelic therapy educational platform Fluence to provide design and training for the psychotherapeutic portion of its Phase 2a clinical trials for treating eating disorders and fibromyalgia. “Fluence is led by researchers and psychotherapists with direct experience in conducting psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals that are administering psychedelic compounds to patients,” reads a recent article. The piece quotes Tryp President and Chief Science Officer Jim Gilligan as saying, “In the fast-moving arena of psychedelic therapies, Fluence has established themselves as the leader in…

Continue Reading

TuesdayJun 15, 2021 12:37 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Looks to Focus Expertise on Psychedelic Drug Formulation as Manufacturing Programs Advance

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community. The audio press release discusses the company’s recent announcement regarding the status of its GMP mescaline synthesis program. “With both its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production underway, the first stage of XPhyto's psychedelic medicine program is progressing on schedule. As the manufacturing programs advance,…

Continue Reading

TuesdayJun 15, 2021 10:39 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Addition to Russell 2000, 3000 Indexes

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics (“DTx”) market, will be joining the broad-market Russell 3000(R) Index and the small-cap Russell 2000(R) Index at the conclusion of the Russell U.S. Indexes annual reconstitution, which will be effective after the U.S. equity markets open on Monday, June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021. The annual reconstitution of the Russell indexes identifies the 4,000 largest U.S. stocks as of May 7, 2021; it also ranks them by total market capitalization. Once a company joins the Russell 3000 Index, the membership lasts for one year, until the index conducts its annual reconstitution.…

Continue Reading

FridayJun 11, 2021 11:21 am

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Disposable Technology Vital Amid Ongoing Pandemic

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed sanitary, disposable EEG caps that are proving useful amid the ongoing pandemic. “When fighting a highly contagious disease, disposable technology is vital,” notes a recent article. This is where NeuroCap(TM) and NeuroEEG(TM), the company’s two FDA-cleared devices, can help. They offer cost-efficient, portable neurological monitoring.” The article observes that EEGs may offer a much-needed solution given that neurological conditions associated with COVID-19 are challenging to diagnose. “For example, the diagnosis of encephalopathy, one of the most frequently occurring neurological conditions in COVID-19, is mainly…

Continue Reading

ThursdayJun 10, 2021 1:01 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Subsidiary Publishes Data Report on Medical Cannabis Use for Pain Management

RYAH Group (CSE: RYAH) today announced that its wholly owned subsidiary, RYAH Medtech Inc., has published a data report on the use of medical cannabis among patients with pain conditions. According to the update, the report features insights into the use of cannabis to treat pain conditions by patients within the RYAH Data ecosystem and whether cannabis may be one of the alternative treatment solutions to reduce opioid use-related problems associated with existing treatment options. “The RYAH data report on cannabis use for pain management comes at a turning point as studies on alternatives to opioids in treatment and potential…

Continue Reading